Healthcare Services

Immunoglobulin A IgA Vasculitis Market Growth Outlook Indicating Expansion To $2.2 Billion By 2030

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Trend Is Expected For The Immunoglobulin A IgA Vasculitis Market From 2026 To 2030?

The market for immunoglobulin A (IgA) vasculitis has experienced robust expansion in recent times. This market is projected to expand from $1.63 billion in 2025 to $1.74 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. Historically, this growth can be ascribed to several factors, including enhanced clinical comprehension of IgA-mediated autoimmune conditions, a rise in the diagnosis of pediatric vasculitis, more extensive application of corticosteroids and immunosuppressive medications, an increase in hospital-provided autoimmune care, and the broadening expertise within nephrology.

The immunoglobulin a iga vasculitis market size is anticipated to undergo significant expansion in the coming years. It is projected to reach $2.21 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.2%. This growth during the forecast period can be attributed to increasing research into novel immunomodulatory drugs, a rising adoption of personalized autoimmune therapies, a growing focus on sustained renal protection, the expansion of biologic treatment pipelines, and advancements in diagnostic imaging and biopsy techniques. Prominent trends expected in the forecast period include an increasing emphasis on early and accurate disease diagnosis, a rising uptake of targeted immunosuppressive therapies, the growing utilization of biomarker-based disease monitoring, the expansion of personalized treatment approaches, and an enhanced focus on renal outcome management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24567&type=smp

What Important Drivers Are Powering The Immunoglobulin A IgA Vasculitis Market Growth?

An increasing occurrence of autoimmune conditions is anticipated to drive expansion in the immunoglobulin A (IgA) vasculitis market in the future. These are disorders where the body’s immune system erroneously targets its own healthy cells, tissues, or organs, rather than defending against infections and foreign entities. The increasing frequency of these disorders is largely attributed to greater exposure to pollutants, which can disturb immune system regulation and provoke irregular reactions. Immunoglobulin A (IgA) vasculitis assists in addressing autoimmune diseases by initiating an immune response that causes inflammation in small blood vessels, thereby supporting the comprehension and prospective therapy of diverse autoimmune ailments. For example, data from February 2024, provided by the Vasculitis Foundation, a US-based non-profit, indicates that the yearly incidence of IgA vasculitis among U.S. adults stands at approximately 2 cases per 100,000, though global rates show significant variation, falling between approximately 60 and 550 cases per million. Consequently, the escalating occurrence of autoimmune diseases is fueling the expansion of the immunoglobulin A (IgA) vasculitis market.

Which Segment Divisions Form The Structure Of The Immunoglobulin A IgA Vasculitis Market?

The immunoglobulin a iga vasculitis market covered in this report is segmented –

1) By Treatment Type: Medications, Plasma Exchange, Supportive Care, Immunosuppressive Therapy

2) By Diagnosis Method: Blood Tests, Urinalysis, Imaging Studies, Biopsy

3) By Route Of Administration: Oral, Injectables

4) By End User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Medications: Corticosteroids, Immunosuppressants, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil

2) By Plasma Exchange: Therapeutic Plasma Exchange, Plasma Filtration

3) By Supportive Care: Pain Management, Kidney Function Support, Blood Pressure Management

4) By Immunosuppressive Therapy: Methotrexate, Rituximab

What Trends Are Shaping The Immunoglobulin A IgA Vasculitis Market Structure?

Leading companies active in the immunoglobulin A (IgA) vasculitis market are concentrating on developing novel treatments, such as targeted biologics and immunomodulators, with the aim of reducing inflammation and preventing renal complications. These targeted biologics and immunomodulators represent advanced therapies that modulate specific immune pathways to diminish inflammation and avert immune-mediated damage in IgA vasculitis. As an illustration, in April 2025, Novartis AG, a pharmaceutical company based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan), designated for the treatment of primary immunoglobulin A nephropathy (IgAN). Vanrafia serves as a once-daily, oral, selective endothelin A receptor antagonist formulated to reduce proteinuria in adults suffering from primary IgAN who face a risk of rapid disease progression. This medication can be integrated into existing supportive care regimens without the necessity of a risk evaluation and mitigation strategy (REMS).

Which Firms Are Competing In The Immunoglobulin A IgA Vasculitis Market?

Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd

Access The Complete Immunoglobulin A IgA Vasculitis Market Report:

https://www.thebusinessresearchcompany.com/report/immunoglobulin-a-iga-vasculitis-global-market-report

Which Region Commands The Largest Share Of The Immunoglobulin A IgA Vasculitis Market?

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin a iga vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Immunoglobulin A IgA Vasculitis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24567&type=smp

Browse Through More Reports Similar to the Global Immunoglobulin A IgA Vasculitis Market 2026, By The Business Research Company

Immunodiagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report

Veterinary Autoimmune Disease Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-autoimmune-disease-therapeutics-global-market-report

Intravenous Immunoglobulin Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795